Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Alaska
Clinical trial register · United States · industry-sponsored

Clinical Trials in Alaska, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 Merck Sharp & Dohme LLC11 Bristol-Myers Squibb6 Gilead Sciences5 Novartis Pharmaceuticals4
State
California5309 Florida4445 Illinois2491 Georgia2363 Arizona2246
All 51 states
Target enrolment
to

Trials with a site in Alaska

99 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Ecotera Health LLC
Observational
15
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-10-21
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Alaska, Maryland, Michigan, New York, Ohio, Pennsylvania, West Virginia
2026-09-29
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Hawaii
2026-05-22
Recruiting
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
Amgen
Phase 3
270
Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Recruiting
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Alabama, Alaska, California, Florida, Georgia, Louisiana, Maryland, Minnesota
2026-01-19
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Alaska, Arizona, Arkansas, California, Delaware, Florida, Idaho, Illinois
2026-01-02
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-22
Recruiting
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
Daiichi Sankyo
Phase 3
686
Alaska, California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Minnesota
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Active, closed
Bristol-Myers Squibb
Phase 2
76
Alaska, California, Idaho, Ohio, Pennsylvania
2025-09-19
Recruiting
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
Alaska, Florida, Louisiana, Nebraska, New Jersey, New York, Ohio, Texas
2025-08-11
Recruiting
Celgene
Phase 3
400
Alabama, Alaska, Arkansas, California, Florida, Georgia, Illinois, Iowa
2025-07-28
Recruiting
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
BiomX Ltd
Phase 2
63
Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York
2025-07-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Kansas
2025-04-09
Recruiting
Gilead Sciences
Phase 3
695
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maine
2025-04-04
Recruiting
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Recruiting
Hoffmann-La Roche
Phase 2
130
Alaska, California, Colorado, Florida, Idaho, Illinois, Iowa, Kentucky
2025-03-05
Recruiting
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Active, closed
Genmab
Phase 3
584
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Recruiting
Boehringer Ingelheim
Phase 2
588
Alaska, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2024-10-11
Active, closed
Celgene
Phase 2
95
Alabama, Alaska, Arizona, California, District of Columbia, Florida, Kansas, Minnesota
2024-08-30
Recruiting
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Active, closed
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Alabama, Alaska, Arizona, California, Florida, Georgia, Louisiana, Nevada
2024-07-24
Active, closed
Celgene
Phase 3
850
Alabama, Alaska, Arizona, California, Florida, Georgia, Illinois, Iowa
2024-06-19
Recruiting
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Recruiting
AstraZeneca
Phase 3
440
Alaska, Arizona, Arkansas, California, Colorado, Delaware, Florida, Georgia
2024-05-20
Recruiting
AstraZeneca
Phase 3
675
Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2024-04-11
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida
2024-02-28
Recruiting
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Alaska, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Minnesota
2024-02-21
Recruiting
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482Antineutrophil Cytoplasmic Antibody-associated Vasculitis
DrugAvacopan
Amgen
Phase 4
300
Alaska, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2024-02-07
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Alabama, Alaska, Arizona, California, Georgia, Illinois, Indiana, Kansas
2024-02-05
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
BeOne Medicines
Phase 3
652
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-11-11
Active, closed
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Alaska, California, Colorado, Connecticut, District of Columbia, Florida, Hawaii, Illinois
2023-09-18
Active, closed
Amgen
Phase 3
509
Alabama, Alaska, Arkansas, California, Illinois, Indiana, Iowa, Kentucky
2023-05-31
Recruiting
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana
2023-03-29
Active, closed
BeiGene
Phase 1/2
113
Alaska, Arizona, California, Florida, Indiana, Kentucky, Louisiana, Missouri
2023-01-29
Active, closed
Amgen
Phase 3
7,297
Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida
2022-12-14
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2022-11-11
Recruiting
Acrivon Therapeutics
Phase 2
350
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2022-08-29
Recruiting
Bristol-Myers Squibb
Observational
1,700
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-08-16
Active, closed
Genentech, Inc.
Phase 3
373
Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-08-03
Active, closed
Gilead Sciences
Phase 3
443
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-07-25
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Alaska, Arizona, Colorado, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2022-07-21
Active, closed
Daiichi Sankyo
Phase 3
586
Alaska, Arkansas, California, Florida, Georgia, Idaho, Maryland, Massachusetts
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2022-07-08
Active, closed
Nevro Corp
Not applicable
497
Alaska, Michigan, Ohio, Oklahoma, Oregon, Pennsylvania, Virginia
2022-07-05
Active, closed
Gilead Sciences
Phase 2
193
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2022-05-30
Active, closed
STOP AF First Post-Approval Study
NCT05227053Paroxysmal Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alaska, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan, Ohio
2022-04-28
Active, closed
AstraZeneca
Phase 3
390
Alaska, California, Colorado, Delaware, Georgia, Illinois, Maryland, New Jersey
2022-02-21
Active, closed
Genentech, Inc.
Phase 2
320
Alabama, Alaska, Arizona, California, Colorado, Delaware, Florida, Iowa
2022-02-01
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
2021-11-23
Active, closed
Gilead Sciences
Phase 3
603
Alaska, Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas
2021-11-17
Active, closed
AstraZeneca
Phase 3
454
Alaska, California, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania
2021-10-28
By invitation
Cytokinetics
Phase 2/3
900
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2021-05-06
Active, closed
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
NCT04825743ST-elevation Myocardial Infarction (STEMI)
CeleCor Therapeutics
Phase 3
2,463
Alaska, Michigan, Missouri, Texas
2021-04-24
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Alaska, Arizona, California, Colorado, Florida, Kentucky, Louisiana, Maryland
2021-04-08
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Alaska, Arizona, California, Florida, Louisiana, Maryland, Michigan, Nebraska
2021-03-18
Active, closed
Kiniksa Pharmaceuticals International, plc
Observational
500
Alaska, Arizona, California, Illinois, Iowa, Maryland, Massachusetts, Michigan
2021-03-16
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kansas, Massachusetts
2020-06-08
Active, closed
Gilead Sciences
Phase 2
227
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Illinois, Indiana
2019-10-15
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Alaska, California, Connecticut, Delaware, Florida, Illinois, Kentucky, Maryland
2019-09-17
Active, closed
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
DrugsAdagrasib·Afatinib·Cetuximab·Pembrolizumab
Mirati Therapeutics Inc.
Phase 1/2
731
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2019-01-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2018-12-24
Active, closed
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsPD-L1 t-haNK·Avelumab·Atezolizumab·Durvalumab
ImmunityBio, Inc.
Phase 2
40
Alaska, Arkansas, California, Florida, Indiana, Iowa, Kentucky, Massachusetts
2018-12-11
Active, closed
AstraZeneca
Phase 3
895
Alabama, Alaska, Arizona, California, Colorado, Illinois, Indiana, Louisiana
2018-10-31
Active, closed
Tesaro, Inc.
Phase 3
1,400
Alaska, Arizona, California, Connecticut, Florida, Illinois, Louisiana, Maine
2018-10-11
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2018-03-23
Active, closed
AstraZeneca
Phase 2
273
Alabama, Alaska, Arizona, Colorado, Connecticut, Illinois, Indiana, Kentucky
2018-03-07
Active, closed
Pfizer
Phase 3
1,054
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2017-12-18
Active, closed
Medtronic
Observational
1,092
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2017-08-21
Active, closed
Eli Lilly and Company
Phase 3
5,637
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2017-07-12
Active, closed
ImmunityBio, Inc.
Phase 2/3
190
Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois
2017-06-02
Recruiting
Agendia
Observational
30,000
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2017-04-28
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
Alaska, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2017-03-24
Recruiting
Stryker Instruments
Observational
8,000
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2017-03-10
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Indiana
2016-12-22
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2014-12-17
Active, closed
ImmunityBio, Inc.
Phase 1/2
369
Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia
2014-07-21
Active, closed
AstraZeneca
Phase 3
1,837
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2014-04-22
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Idaho
2013-10-14
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2013-08-26
Recruiting
Medtronic
Observational
20,000
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
1983-01
Rows per page Showing 1–99 of 99
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/alaska

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 99 of those studies with a site in Alaska.

How many clinical trials are recruiting in Alaska?

42 of the 99 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 55 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Alaska), 99 studies
PhaseStudiesRecruitingShare
Phase 3592559.6%
Phase 219619.2%
Observational969.1%
Phase 2/3535.1%
Phase 1/2404%
Not applicable101%
Phase 1111%
Phase 4111%

Most active sponsors

Lead sponsors with the most studies (Alaska)
Lead sponsorStudiesRecruiting
AstraZeneca158
Merck Sharp & Dohme LLC115
Bristol-Myers Squibb63
Gilead Sciences51
Amgen42
Novartis Pharmaceuticals41
Celgene31
Daiichi Sankyo32
Hoffmann-La Roche32
ImmunityBio, Inc.30
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.